<p>/PRNewswire/ -- 羅森律師事務所是一家全球投資者權益律師事務所，宣佈代表在 2022 年 10 月 31 日至 2024 年 8 月 2 日（包括這兩個日期）期間購買 Actinium Pharmaceuticals, Inc.（紐約證券交易所代碼：ATNM）證券的投資者提起集體訴訟（“集體訴訟期間”）。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 5 月 26 日之前向法院提出申請。</p>
<p>那麼，您在集體訴訟期間購買了 Actinium 證券，可能有權獲得賠償，而無需支付任何自掏腰包的費用或成本，採用風險代理費用安排。</p>
<p>接下來該怎麼做：要加入 Actinium 集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=37511 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 5 月 26 日之前向法院提出申請。首席原告是代表其他集體成員指導訴訟的代表方。</p>
<p>為什麼選擇羅森律師事務所：我們鼓勵投資者選擇在領導角色上有成功記錄的合格律師事務所。通常，發佈通知的律師事務所沒有可比的經驗、資源或任何有意義的同行認可。在選擇律師時要明智。羅森律師事務所代表全球投資者，專注於證券集體訴訟和股東衍生訴訟。羅森律師事務所曾在當時獲得針對一家中國公司的最大證券集體訴訟和解。2017 年，羅森律師事務所被 ISS 證券集體訴訟服務評選為證券集體訴訟和解數量第一名。自 2013 年以來，該事務所每年都排名前四，併為投資者追回了數億美元。僅在 2019 年，該事務所就為投資者爭取了超過 4.38 億美元。在 2020 年，創始合夥人 Laurence Rosen 被 law360 評選為原告律師界的巨頭。該事務所的許多律師已獲得 Lawdragon 和 Super Lawyers 的認可。</p>
<p>案件詳情：根據訴訟，集體訴訟期間，被告作出了虛假和/或誤導性的陳述，和/或未能披露以下內容：（1）Actinium 的 Sierra 試驗數據不太可能滿足美國食品和藥物管理局（“FDA”）對 Actinium 的 Iomab-B 生物製品許可申請（“BLA”）的接受和批准的指導方針；（2）包括長期跟蹤在內的額外分析，聲稱展示了改善總體生存率（“OS”）的趨勢，Actinium 向 FDA 提供的這些數據試圖減輕 Sierra 試驗的糟糕 OS 數據，但不太可能滿足 FDA 對 Actinium 的 Iomab-B BLA 的接受和批准的指導方針；（3）因此，FDA 可能會拒絕審查 Iomab-B BLA，或者如果考慮該 BLA，該申請在當前形式下不太可能獲得批准；（4）因此，被告對 Actinium 的業務、運營和前景的積極陳述在實質上具有誤導性，和/或缺乏合理依據。當真實細節進入市場時，訴訟聲稱投資者遭受了損失。</p>
<p>要加入 Actinium 集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=37511 https://rosenlegal.com/submit-form/?case_id=28116 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。</p>
<p>尚未認證集體。直到集體被認證，您不會被律師代表，除非您聘請一位。您可以選擇您自己的律師。您也可以選擇保持缺席集體成員身份，此時不採取任何行動。投資者分享任何潛在未來賠償的能力並不依賴於擔任首席原告。</p>
<p>請關注我們的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm 或在 Twitter 上：https://twitter.com/rosen_firm 或在 Facebook 上：https://www.facebook.com/rosenlawfirm。</p>
<p>律師廣告。之前的結果並不保證類似的結果。</p>
<p>聯繫信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>羅森律師事務所，P.A.</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>紐約， NY 10016</p>
<p>電話: (212) 686-1060</p>
<p>免費電話: (866) 767-3653</p>
<p>傳真: (212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>來源：羅森律師事務所，P.A.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzI5Jk5ld3NJdGVtSWQ9REM1MzAyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMjkxMzE1UFJfTkVXU19VU1BSX19fX19EQzUzMDIx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzI5Jk5ld3NJdGVtSWQ9REM1MzAyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMjkxMzE1UFJfTkVXU19VU1BSX19fX19EQzUzMDIx"/></p>

Actinium制藥

<p>羅森律師事務所代表 Actinium Pharmaceuticals, Inc.（紐約證券交易所美國：ATNM）的投資者提起了集體訴訟，指控其在 2022 年 10 月 31 日至 2024 年 8 月 2 日期間存在證券欺詐。投資者可能有權獲得賠償，無需預付費用。訴訟指控 Actinium 在其 Iomab-B 生物製品許可證申請中做出了誤導性陳述，該申請可能不符合 FDA 的指導方針。有興趣的投資者可以在 2025 年 5 月 26 日之前聯繫該事務所加入集體訴訟</p>

<p>, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the &#34;Class Period&#34;). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 羅森律師事務所是一家全球投資者權益律師事務所，宣佈代表在 2022 年 10 月 31 日至 2024 年 8 月 2 日（包括這兩個日期）期間購買 Actinium Pharmaceuticals, Inc.（紐約證券交易所代碼：ATNM）證券的投資者提起集體訴訟（“集體訴訟期間”）。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 5 月 26 日之前向法院提出申請。</p>
</div><p>So What: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那麼，您在集體訴訟期間購買了 Actinium 證券，可能有權獲得賠償，而無需支付任何自掏腰包的費用或成本，採用風險代理費用安排。</p>
</div><p>What to do next: To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下來該怎麼做：要加入 Actinium 集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=37511 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 5 月 26 日之前向法院提出申請。首席原告是代表其他集體成員指導訴訟的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>為什麼選擇羅森律師事務所：我們鼓勵投資者選擇在領導角色上有成功記錄的合格律師事務所。通常，發佈通知的律師事務所沒有可比的經驗、資源或任何有意義的同行認可。在選擇律師時要明智。羅森律師事務所代表全球投資者，專注於證券集體訴訟和股東衍生訴訟。羅森律師事務所曾在當時獲得針對一家中國公司的最大證券集體訴訟和解。2017 年，羅森律師事務所被 ISS 證券集體訴訟服務評選為證券集體訴訟和解數量第一名。自 2013 年以來，該事務所每年都排名前四，併為投資者追回了數億美元。僅在 2019 年，該事務所就為投資者爭取了超過 4.38 億美元。在 2020 年，創始合夥人 Laurence Rosen 被 law360 評選為原告律師界的巨頭。該事務所的許多律師已獲得 Lawdragon 和 Super Lawyers 的認可。</p>
</div><p>Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Actinium's data from Sierra Trial was unlikely to satisfy the U.S. Food and Drug Administration's (&#34;FDA&#34;) guidelines for the acceptance and approval of Actinium's Iomab-B Biologics License Application (&#34;BLA&#34;); (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival (&#34;OS&#34;) that Actinium provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Actinium's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4) as a result, defendants' positive statements about Actinium's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件詳情：根據訴訟，集體訴訟期間，被告作出了虛假和/或誤導性的陳述，和/或未能披露以下內容：（1）Actinium 的 Sierra 試驗數據不太可能滿足美國食品和藥物管理局（“FDA”）對 Actinium 的 Iomab-B 生物製品許可申請（“BLA”）的接受和批准的指導方針；（2）包括長期跟蹤在內的額外分析，聲稱展示了改善總體生存率（“OS”）的趨勢，Actinium 向 FDA 提供的這些數據試圖減輕 Sierra 試驗的糟糕 OS 數據，但不太可能滿足 FDA 對 Actinium 的 Iomab-B BLA 的接受和批准的指導方針；（3）因此，FDA 可能會拒絕審查 Iomab-B BLA，或者如果考慮該 BLA，該申請在當前形式下不太可能獲得批准；（4）因此，被告對 Actinium 的業務、運營和前景的積極陳述在實質上具有誤導性，和/或缺乏合理依據。當真實細節進入市場時，訴訟聲稱投資者遭受了損失。</p>
</div><p>To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Actinium 集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=37511 https://rosenlegal.com/submit-form/?case_id=28116 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未認證集體。直到集體被認證，您不會被律師代表，除非您聘請一位。您可以選擇您自己的律師。您也可以選擇保持缺席集體成員身份，此時不採取任何行動。投資者分享任何潛在未來賠償的能力並不依賴於擔任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.</p>
<div class="lb-trans"><p>請關注我們的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm 或在 Twitter 上：https://twitter.com/rosen_firm 或在 Facebook 上：https://www.facebook.com/rosenlawfirm。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律師廣告。之前的結果並不保證類似的結果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>聯繫信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>羅森律師事務所，P.A.</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>紐約， NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>電話: (212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免費電話: (866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>傳真: (212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>來源：羅森律師事務所，P.A.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzI5Jk5ld3NJdGVtSWQ9REM1MzAyMSZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMjkxMzE1UFJfTkVXU19VU1BSX19fX19EQzUzMDIx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC53021&amp;Transmission_Id=202503291315PR_NEWS_USPR_____DC53021&amp;DateId=20250329"/></p>

13:15 ET
			
			
				ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

ATNM 投資者有機會領導 ROSEN，這是一家全國知名的投資者顧問公司，鼓勵對 Actinium 製藥公司的證券欺詐提起訴訟